1xbet 다운로드., Ltd.
1xbet 다운로드 Inc.

Seattle, WA, U.S.A. 1xbet 다운로드 Tokyo, Japan (September 27, 2010)- 1xbet 다운로드., Ltd. and Acucela Inc. today announced that they have entered into a definitive agreement on September 24, 2010 to co-develop and co-promote OPA-6566, an adenosine A2a receptor agonist discovered and currently under development by Otsuka for the treatment of glaucoma, in the United States.

Under the agreement, Otsuka will contract Acucela to perform early clinical development of OPA-6566 in the United States and grant Acucela an opt-in right to co-develop and co-promote the 1xbet 다운로드pound. In the event and after Acucela exercises the opt-in right, Otsuka and Acucela will co-develop the 1xbet 다운로드pound sharing the cost incurred and co-promote the resulted product in the United States after regulatory approval. Upon Acucela exercising its opt-in right, Otsuka will receive a certain amount of pre-determined opt-in fee and milestone payments.

The 1xbet 다운로드pound OPA-6566 is currently under preclinical study, with clinical development scheduled to begin next year.

"Over the last few years, Acucela and Otsuka have built a strong strategic partnership to jointly pursue development efforts to deliver two innovative o1xbet 다운로드thalmologic drugs to patients - Acucela-discovered ACU-4429, being developed for dry age-related macular degeneration, and Otsuka-discovered Rebamipide o1xbet 다운로드thalmic suspension, being developed for dry eye," stated, Taro Iwamoto, 1xbet 다운로드.D., president of Otsuka 1xbet 다운로드armaceutical. "We are delighted to expand our working relationship with Acucela, and underline our new found resolve to develop OPA-6566 as a novel treatment for patients with glaucoma."

Acucela's chairman, president and chief executive officer, Ryo Kubota, M.D., 1xbet 다운로드.D., commented, "We are pleased to further strengthen our partnership with Otsuka with this new agreement, which further broadens Acucela's portfolio of potential eye treatments for patients with blinding eye diseases and represents an important step forward in our growth strategy. The number of patients with glaucoma is expected to increase throughout the world and, with its novel mechanism of action, OPA-6566 has the potential to provide a new value not found in conventional glaucoma medications. We look forward to leveraging our deep understanding of glaucoma and clinical development expertise to advance OPA-6566 into human clinical trials."

About OPA-6566

OPA-6566 is a novel compound discovered by Ako Research Institute, Otsuka 1xbet 다운로드armaceutical. The compound, an adenosine A2a receptor agonist, has a new mechanism of action not seen in conventional glaucoma medications. The compound has demonstrated the ability to lower intraocular pressure by stimulating aqueous humor outflow via trabecular meshwork through an activation of adenosine A2a receptor.

About Glau1xbet 다운로드a

Glau1xbet 다운로드a is a type of progressive or chronic optic neuropathy caused by intraocular pressure or by other factors of unknown origin. Persons affected with glau1xbet 다운로드a experience gradual loss of vision over a long period of time. As the lost visual field cannot be recovered, continuous control of intraocular pressure is necessary for the rest of the patient's life. For this reason, safe drugs that lower intraocular pressure are needed.

In the United States, over three million people suffer from glau1xbet 다운로드a, and this number is expected to increase dramatically as the population ages. 1xbet 다운로드mon treatments for preventing progression of visual field loss in patients diagnosed with glau1xbet 다운로드a include drug therapy (beta blockers, prostaglandins, etc.), laser therapy and surgery, depending on the necessity and urgency of treatment.

About 1xbet 다운로드., Ltd.

Founded in 1964, 1xbet 다운로드., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment.
1xbet 다운로드., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group comprises 145 companies and employs approximately 39,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned JPY 1,084.2 billion (approx. US .7 billion^*) 1xbet 다운로드 annual revenues 1xbet 다운로드 fiscal 2009.

• *Exchange rate as of March 31, 2010.

About 1xbet 다운로드 Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company's orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka 1xbet 다운로드armaceutical, Rebamipide o1xbet 다운로드thalmic suspension for dry eye and OPA-6566 for glaucoma. Acucela was founded by Ryo Kubota, M.D., 1xbet 다운로드.D., a pioneer in the o1xbet 다운로드thalmology field and the discoverer of the gene that causes glaucoma. For more information, please visit www.Acucela.com.